PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H
SCHOFIELD, Wis., Dec. 23, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced it received the initial funding to begin final production of MigraPure® H, a hemp-based, advanced headache relief product, for planned distribution to 1,000 medical and recreational marijuana dispensaries in Colorado, Washington State, and California.
With the MigraPure H Advanced headache relief gel formulation completed, PuraMed BioScience has turned its attention toward the packaging for the initial launch. The Company announced it has received its first round of funding, under its agreement with FastFunds Financial Corporation (FFFC), which will be used to finalize production, packaging and labeling of MigraPure H.
"The investment of FastFunds Financial puts us one step closer to shipping MigraPure H," said Russell Mitchell, CEO and Chairman of PuraMed BioScience. "With all the recent legislative changes happening, the opportunity to break into the cannabis market at this point is exciting. We hope to have our first shipment of MigraPure H delivered to dispensaries by the end of February.
"In addition to the dispensaries, we have several other independent concerns interested in MigraPure H," said Mitchell. "The year ahead looks promising."
PuraMed BioScience has finalized the package design and is nearing completion of the labeling.
As of Dec. 05, 2014, the Company had approximately 216 million common shares issued and outstanding.
About MigraPure and MigraPure H
MigraPure Advanced Migraine Relief is a sublingual feverfew and ginger gel that was clinically tested under the name LipiGesic® M. The peppermint flavor of this homeopathic, all-natural, over-the-counter migraine headache pain reliever has been enhanced, but the clinically tested active ingredients remain the same.
MigraPure H Advanced Headache Relief is PuraMed's most recent all-natural, hemp-based headache reliever. The active ingredients in MigraPure have been combined with a hemp-base to create a powerful treatment for migraines and seizure-related headaches. Early indications show the formulation may also be effective for tension and cluster headaches and other epilepsy symptoms.
MigraPure H does not violate any Federal laws pertaining to the cultivation, distribution or marketing of a controlled or banned substance.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products.
PuraMed BioScience also specializes in the development of sublingual homeopathic medications. This type of formulation delivers active ingredients directly into the bloodstream for faster relief and greater effectiveness with fewer side effects than their chemical counterparts. www.PuraMedBioScience.com
Forward-Looking Statements: This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russ Mitchell
[email protected]
Phone: 715.359.6373
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/puramed-bioscience-nears-final-stages-needed-for-distribution-of-migrapure-h-300013461.html
SOURCE PuraMed BioScience, Inc.
Share this article